Andina Acquisition Corp. III ANDA
Set alert
9.20 0.00 0.00%
At close
8.90 Day range 9.92
52-week range unavailable
- Open
- 9.00
- Prev close
- 9.20
- Mkt cap
- 40.64M
- Vol
- 314.27K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.90
- High
- 9.92
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 9.48
- Inst. own
- 44.22%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.18
- 200-d avg
- 10.54
- 1y target
- 0.00
Key statistics
- Market cap
- 40.64M
- Enterprise value
- 34.83M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.64
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 368.53K
- Total cash
- 77.20K
- Total debt
- 0
- Return on equity
- -168.12%
- Shares outstanding
- 4.42M
- Short % of float
- 12.01%
- 50-day average
- 10.18
- 200-day average
- 10.54
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2021 | Northland Capital Markets | init | — | Outperform |
About Andina Acquisition Corp. III
Andina Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to engage in the business of manufacturing, marketing, and selling healthy snacks products. The company was incorporated in 2016 and is based in Bogotá, Colombia.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- Colombia
News
- Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
- FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
- Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
- Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
- NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
- Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
- Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
- Supernus Announces Paragraph IV ANDA Filings for Qelbree®
- Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
- Hikma acquires Novugen's FDA-approved ANDA for trametinib
Your note
Sign in to keep a note on ANDA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cowen and Company, LLC | 9.28% | 409,967 | 4.21M | Mar 30, 2021 |
| K2 Principal Fund, L.P. | 4.05% | 178,883 | 1.84M | Mar 30, 2021 |
| Tenor Capital Management Co., L.p. | 3.55% | 156,979 | 1.61M | Mar 30, 2021 |
| Cooper Creek Partners Management LLC | 2.78% | 122,914 | 1.26M | Mar 30, 2021 |
| AWM Investment Company, Inc. | 2.26% | 100,000 | 1.03M | Mar 30, 2021 |
| Ophir Asset Management Pty Ltd | 1.93% | 85,217 | 875.18K | Mar 30, 2021 |